Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes
Table 2
Maternal and fetal outcomes in pregnant women receiving ILPS or NPH insulin.
ILPSg
NPHg
Number of subjects
Total
T2DM
GDM
Total
T2DM
GDM
53
7
46
36
18
18
Maternal outcome
Gestational week at delivery
38.3 1.4
38.4 2.1
38.3 1.3
38.6 1.0
38.9 0.9
38.4 1.1
Caesarean section (%)
67.9
100
65.2
80.5
100
61.1
Preterm delivery (%)
7.5
0
8.7
2.8
0
5.5
Hypertensive disorders (%)
20.7
42.8
17.4
38.9
44.4*
33.3
Neonatal outcome
Newborn weight (g)
3328.5 517.1
3104.3 444.7
3361.3 523.5
3376.3 604.2
3338.5 669.3
3409.4 561.2
LGA (%)
15.1
14.3
15.2
22.2
22.2
22.2
PI (g/cm3)
2.2 0.3
2.1 0.3
2.2 0.3
2.3 0.3
2.3 0.4
2.3 0.3
PI > 2.85 g/cm3 (%)
0
0
0
8.3
5.5
11.1
APGAR at 5′
9.7 0.5
9.8 0.4
9.7 0.5
9.5 0.7
9.4 0.8
9.6 0.5
Congenital malformations (%)
3.8
0
4.3
2.8
0
5.5
Neonatal hypoglycemia (%)
7.5
0
8.7
8.3
11.1
5.5
Hyperbilirubinemia (%)
9.4
0
10.9
8.3
11.1
5.5
T2DM: type 2 diabetes mellitus; GDM: gestational diabetes mellitus; LGA: large for gestational age; PI: ponderal index. ILPS versus NPH = 0.02.
